Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mix-up Of Two Anti-Hypertension Drugs Sold In U.S. Prompts India's Lupin To Recall Product

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - One of India's leading pharmaceutical companies Lupin Laboratories Ltd. has initiated a recall of its key ACE inhibitor lisinopril. Lupin had U.S. sales of roughly $45 million from the single drug, said a source closely tracking the news

You may also be interested in...



Outsourcing Your Way Into Trouble: Pfizer Issues Recall After Indian Aurobindo Mislabels Bottles

India-based Aurobindo Pharma Ltd. may find itself in a little hot water with business partner Pfizer Inc. after forcing a recall because bottles of an anti-depressant drug may have been mislabeled as a benign prostatic hyperplasia treatment

14 Months After U.S. FDA Charged India's Lupin, Manufacturing Facility At Mandideep Cleared

MUMBAI - A long trail of hair splitting audits and investigations came to an end for India's drug maker Lupin as U.S. FDA issued an "All Clear" statement for the company's Mandideep manufacturing site in the central Indian state of Madhya Pradesh

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC077696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel